ISRCTN83167415招募中不适用
Prediction of trastuzumab-associated cardiomyopathy using cardiovascular MRI
Working Group Cardiac MRI @ Charité University Medicine Berlin & HELIOS Hospital Berlin-Buch0 个研究点目标入组 30 人开始时间: 2018年11月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Mammary carcinoma
- •2. Planned trastuzumab therapy
排除标准
- •1. Any absolute contraindication for MRI
- •2. Chronic renal failure with GFR <30 ml/min/m2 at time of inclusion
研究者
相似试验
已完成
不适用
Prediction of trastuzumab-induced cardiotoxicity using transthoracic echocardiography and cardiac biomarkers in patients with gastric cancerCancer therapeutics-related cardiac dysfunctionJPRN-UMIN000030429Cancer Institute Hospital48
招募中
不适用
Predictors of Trastuzumab-induced Cardiotoxicity in Breast Cancer PatientsBreast cancer patientTrastuzumabCardiotoxicityBreast cancerTCTR20210209001Faculty of medicine, Chiang Mai University250
已完成
2 期
The effect of anti-HER2 therapy in metastatic breast cancer wih HER2-negative primary tumor but HER2-positive circulating tumor cells<p>Breast cancer, borstkanker, HER2, ER, PIK3CA, CTC, circulating tumor cell, circulerende tumorcellen, metastasen, metastasis, trastuzumab, herceptin, docetaxel</p>10006232NL-OMON20549Erasmus MC Cancer Institute, department of Medical Oncology18
终止
2 期
Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance ImagingCancer, BreastLV DysfunctionNCT01436604Centre Francois Baclesse19
进行中（未招募）
不适用
Efficacy and toxicity of Trastuzumab at the maintaining dose of 1 mg/kg/week versus the standard dose of 2 mg/kg/week in combination with chemotherapy in metastatic breast cancer patients. A phase III multicenter study. - Dose optimization of TrastuzumabEUCTR2007-006060-29-ITIST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO